Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Colorcon
McKinsey
Merck
Medtronic

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR EMBEDA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Embeda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00415597 ↗ Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain Completed Pfizer Phase 3 2006-12-01 Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
NCT00420992 ↗ A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee Completed Pfizer Phase 3 2006-12-01 The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.
NCT01100437 ↗ Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients Terminated Pfizer Phase 4 2010-04-01 This study will evaluate whether crushed EMBEDA capsules induce clinical opiate withdrawal signs and symptoms in opioid-dependent patients with chronic non-cancer pain who are stabilized on EMBEDA.
NCT01179191 ↗ Conversion to Embeda With Rescue Trial Terminated Pfizer Phase 4 2010-08-01 The purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be successfully adjusted to a stable dose of EMBEDA (morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's risk for prescription opioid abuse, misuse and diversion.
NCT01380093 ↗ Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users Completed Pfizer Phase 1 2011-02-01 The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to determine the abuse potential of crushed EMBEDA relative to placebo and and to compare the pharmacokinetics and safety of crushed EMBEDA with crushed controlled-release morphine and crushed placebo.
NCT01595867 ↗ Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo Completed Pfizer Phase 1 2010-08-01 This was a single-dose, randomized, double-blind, placebo-controlled, 3 way crossover study designed to evaluate the relative abuse potential of crushed EMBEDA┬« compared to morphine sulfate CR tablets and placebo in healthy male and female, non-dependent, recreational opioid users. An appropriate dose of morphine sulfate CR (i.e., 30 mg, 60 or 90 mg) was to be selected during Part A of the study (Dose Selection Phase). Each subject participated in the study for up to (approximately) 16 weeks and was confined in the clinic for a total of up to 12 nights.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Embeda

Condition Name

Condition Name for Embeda
Intervention Trials
Chronic Pain 3
Pain 2
Chronic Disease 1
Moderate-severe Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Embeda
Intervention Trials
Chronic Pain 3
Opioid-Related Disorders 2
Osteoarthritis 1
Narcotic-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Embeda

Trials by Country

Trials by Country for Embeda
Location Trials
United States 97
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Embeda
Location Trials
Utah 5
Florida 4
California 4
North Carolina 4
Illinois 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Embeda

Clinical Trial Phase

Clinical Trial Phase for Embeda
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Embeda
Clinical Trial Phase Trials
Completed 4
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Embeda

Sponsor Name

Sponsor Name for Embeda
Sponsor Trials
Pfizer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Embeda
Sponsor Trials
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Dow
AstraZeneca
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.